research2guidance
US$ 26.93
glp 1 gip 1 The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect Targeting GLP-1, GIP & GCG
Description
Dose adjustments or therapy changes based on response and tolerability
Step 2: Clinician review
However, in humans, the contribution of bile acid changes to metabolic improvements after bariatric procedures is less clear
doi: 10.1038/s41586-019-1471-1
This is an impactful advancement in T2DM management, as some diabetics may be managing multiple injections per day if on insulin
